Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amiodarone + aprindine + bepridil + disopyramide + flecainide + pilsicainide + procainamide + propafenone
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
This is a combination of eight different antiarrhythmic drugs, each with its own mechanism of action: - **Amiodarone**: A class III antiarrhythmic that blocks potassium currents causing repolarization of the heart muscle - **Aprindine**: A cardiac depressant used in arrhythmias - **Bepridil**: An amine calcium channel blocker with antiarrhythmic properties - **Disopyramide**: A class IA antiarrhythmic that blocks sodium channels - **Flecainide**: A class IC antiarrhythmic that blocks sodium channels - **Pilsicainide**: A class IC antiarrhythmic that blocks sodium channels - **Procainamide**: A class IA antiarrhythmic that blocks sodium channels - **Propafenone**: An antiarrhythmic that works directly on heart tissue to slow nerve impulses
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)KCNH2 (Voltage-gated potassium channel subfamily H member 2)KCNA5 (Ultra-rapid delayed rectifier potassium channel)
Beyond the preview
Go deeper on amiodarone + aprindine + bepridil + disopyramide + flecainide + pilsicainide + procainamide + propafenone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amiodarone + aprindine + bepridil + disopyramide + flecainide + pilsicainide + procainamide + propafenone.